Pindolol

Overview

Pindolol, sold under the brand name Visken among others, is a non-selective beta blocker which is used in the treatment of hypertension. It is also an antagonist of the serotonin 5-HT1A receptor, preferentially blocking inhibitory 5-HT1A autoreceptors, and has been researched as an add-on therapy to various antidepressants, such as clomipramine and the selective serotonin reuptake inhibitors (SSRIs), in the treatment of depression and obsessive–compulsive disorder (OCD).[1–7] WP

Uses, dosage and effects

Medical uses

Pindolol is used for hypertension in the United States, Canada, and Europe, and also for angina pectoris outside the United States. When used alone for hypertension, pindolol can significantly lower blood pressure and heart rate, but the evidence base for its use is weak as the number of subjects in published studies is small. In some countries, pindolol is also used for arrhythmias and prophylaxis of acute stress reactions. It has been used to treat anxiety as well.[2][8][9] WP⚠ Wikipedia itself has flagged this text: medical citation needed.

Risks and side effects

Contraindications

Similar to propranolol with an extra contraindication for hyperthyroidism. In patients with thyrotoxicosis, possible deleterious effects from long-term use of pindolol have not been adequately appraised. Beta-blockade may mask the clinical signs of continuing hyperthyroidism or complications, and give a false impression of improvement. Therefore, abrupt withdrawal of pindolol may be followed by an exacerbation of the symptoms of hyperthyroidism, including thyroid storm.[10] WP

Pindolol has intrinsic sympathomimetic activity and is therefore used with caution in angina pectoris.[10] WP

Interactions

Interactions

Pindolol has been found to robustly potentiate the effects of the serotonergic psychedelic dimethyltryptamine (DMT). This is thought to be due to its serotonin 5-HT1A receptor antagonism, which is thought to disinhibit the effects of DMT.[11–14] WP

Pharmacology

Pharmacodynamics

Pindolol is a first generation, non-selective beta blocker in the class of β-adrenergic receptor antagonists. On the receptor level it is a competitive partial agonist. It possesses intrinsic sympathomimetic activity, meaning it has some degree of agonist effects in the absence of competing ligands. Pindolol shows membrane-stabilizing effects like quinidine, possibly accounting for its antiarrhythmic effects. It also acts as a serotonin 5-HT1A receptor partial agonist (intrinsic activity = 20–25%) or functional antagonist. The drug additionally shows affinity for the serotonin 5-HT1B receptor.[15][16][17] WP

Pharmacokinetics

Pindolol is rapidly and well-absorbed from the gastrointestinal tract. It undergoes some first-pass metabolism leading to an oral bioavailability of 50 to 95%. Patients with uremia may have a reduced bioavailability. Food does not alter the bioavailability, but may increase the resorption. Following an oral single dose of 20 mg peak plasma concentrations are reached within 1 to 2 hours. The effect of pindolol on pulse rate (lowering) is evident after 3 hours. WP

The drug's volume of distribution is 1.2 to 2 L/kg. The plasma protein binding is 40 to 60%. It crosses the blood–brain barrier and can produce centrally mediated side effects. Despite being moderately lipophilic, pindolol showed greater electroencephalogram (EEG) changes than the highly lipophilic propranolol. As a result, lipophilicity does not appear to be the sole determinant of blood–brain barrier permeability of beta blockers.[18][19] WP

Approximately two-thirds of pindolol is metabolized in the liver giving hydroxylates, which are found in the urine as gluconurides and ethereal sulfates. The remaining one-third of pindolol is excreted in urine in unchanged form. WP

Despite the rather short elimination half-life of 3 to 4 hours, hemodynamic effects persist for 24 hours after administration. The half-life is increased to 3 to 11.5 hours in patients with renal impairment, to 7 to 15 hours in elderly patients, and from 2.5 to 30 hours in patients with liver cirrhosis.[18] WP

Research

Depression

Pindolol has been investigated as an add-on drug to antidepressant therapy with SSRIs like fluoxetine in the treatment of depression since 1994. The rationale behind this strategy has its basis in the fact that pindolol is an antagonist of the serotonin 5-HT1A receptor. Presynaptic and somatodendritic 5-HT1A receptors act as inhibitory autoreceptors, inhibit serotonin release, and are pro-depressive in their action. This is in contrast to postsynaptic 5-HT1A receptors, which mediate antidepressant effects. By blocking 5-HT1A autoreceptors at doses that are selective for them over postsynaptic 5-HT1A receptors, pindolol may be able to disinhibit serotonin release and thereby improve the antidepressant effects of SSRIs and clomipramine. The results of augmentation therapy with pindolol have been encouraging in early studies of low quality. A 2015 systematic review and meta-analysis of five randomized controlled trials found no overall significant benefit at 2.5 mg although, with regard to patients with SSRI-resistant depression, "once-daily high-dose pindolol (7.5 mg qd) appears to show a promising benefit in these patients". On the other hand, a 2017 systematic review indicated that pindolol's efficacy has been demonstrated in high evidence studies. Initiating pharmacotherapy with an SSRI plus pindolol might accelerate the SSRI's therapeutic impact. Pindolol's antidepressive efficacy may predominantly result from its ability to desensitize 5-HT1A autoreceptors.[3][4][5][20][21][22] WP

History

History

Pindolol was patented by Sandoz in 1969 and was launched in the US in 1977. Towards end of February 2020 FDA added this product to their "DRUG SHORTAGE" list stating this is due to "Shortage of an active ingredient" and this is likely to be related to Coronavirus outbreak and related supply chain impacts.[23] WP

Chemistry

Formula

C14H20N2O2 PC

CAS number

13523-86-9 PC

Molar mass (g/mol)

248.32 PC

IUPAC name (computed by PubChem)

1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol PC

SMILES

CC(C)NCC(COC1=CC=CC2=C1C=CN2)O PC

InChIKey

JZQKKSLKJUAGIC-UHFFFAOYSA-N PC

PubChem CID

4828

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Drugs.com International brand names for pindolol Page accessed Sept 4, 2015. link 2
2. Journal / agency Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension. The Cochrane Database of Systematic Reviews. November 2014. doi:10.1002/14651858.CD007450.pub2 · PMID 25427719 · PMC6486122
3. Journal / agency Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication. The Journal of Clinical Psychiatry. 1998. PMID 9635544
4. Journal / agency Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs. September 2013. doi:10.1007/s40263-013-0071-0 · PMID 23757185
5. Journal / agency Liu Y, Zhou X, Zhu D, Chen J, Qin B, Zhang Y, Wang X, Yang D, Meng H, Luo Q, Xie P. Is pindolol augmentation effective in depressed patients resistant to selective serotonin reuptake inhibitors? A systematic review and meta-analysis. Human Psychopharmacology. May 2015. doi:10.1002/hup.2465 · PMID 25689398
6. Other Mundo, Emanuela, Emanuela Guglielmo, and Laura Bellodi. "Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double blind, placedo-controlled study." International clinical psychopharmacology 13, no. 5 (1998): 219-224
7. Other Sassano-Higgins, S.A. and Pato, M.T., 2015. Pindolol augmentation of selective serotonin reuptake inhibitors and clomipramine for the treatment of obsessive-compulsive disorder: A meta-analysis. Journal of Pharmacology and Pharmacotherapeutics, 6(1), pp.36-38
8. Journal / agency Boyce TG, Ballone NT, Certa KM, Becker MA. The Use of β-Adrenergic Receptor Antagonists in Psychiatry: A Review. J Acad Consult Liaison Psychiatry. 2021. doi:10.1016/j.jaclp.2020.12.009 · PMID 34210401
9. Journal / agency Archer C, Wiles N, Kessler D, Turner K, Caldwell DM. Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis. J Affect Disord. January 2025. doi:10.1016/j.jad.2024.09.068 · PMID 39271062
10. Other RxMed: Pharmaceutical Information - VISKEN
11. Journal / agency Halman A, Kong G, Sarris J, Perkins D. Drug-drug interactions involving classic psychedelics: A systematic review. J Psychopharmacol. January 2024. doi:10.1177/02698811231211219 · PMID 37982394
12. Journal / agency Thomas K. Toxicology and Pharmacological Interactions of Classic Psychedelics. Curr Top Behav Neurosci. 2024. doi:10.1007/7854_2024_508 · PMID 39042251
13. Journal / agency Zahid Z, Strassman RJ, Qualls CR, Nayak SM. 5-HT1A receptor blockade potentiates the subjective effects of DMT. J Psychopharmacol. May 2026. doi:10.1177/02698811261443696 · PMID 42068196
14. Journal / agency Strassman RJ. Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res. 1996. doi:10.1016/0166-4328(96)00081-2 · PMID 8788488
15. Journal / agency Wiysonge CS, Volmink J, Opie LH. Beta-blockers and the treatment of hypertension: it is time to move on. Cardiovascular Journal of Africa. 2007. PMID 18092107 · PMC4170499
16. Journal / agency Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Current Drug Targets. February 2006. doi:10.2174/138945006775515446 · PMID 16475955
17. Journal / agency Glennon RA. Central serotonin receptors as targets for drug research. J Med Chem. January 1987. doi:10.1021/jm00384a001 · PMID 3543362
18. Journal / agency Golightly LK. Pindolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects. Pharmacotherapy. 1982. doi:10.1002/j.1875-9114.1982.tb04521.x · PMID 6133267
19. Journal / agency Drayer DE. Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers. Pharmacotherapy. 1987. doi:10.1002/j.1875-9114.1987.tb04029.x · PMID 2891122
20. Other Pérez, V., Gilaberte, I., Faries, D., Alvarez, E. and Artigas, F., 1997. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. The Lancet, 349(9065), pp.1594-1597
21. Journal / agency Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Köhler S. Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence. European Neuropsychopharmacology. May 2017. doi:10.1016/j.euroneuro.2017.03.003 · PMID 28318897
22. Journal / agency Haddjeri N, Blier P. Effects of sustained (+/-)pindolol administration on serotonin neurotransmission in rats. Journal of Psychiatry & Neuroscience. September 2000. PMID 11022403 · PMC1407726
23. Other Discovery and Development of Major Drugs. Chapter 2 in Pharmaceutical Innovation: Revolutionizing Human Health. Volume 2 of Chemical Heritage Foundation series in innovation and entrepreneurship. Eds Ralph Landau, Basil Achilladelis, Alexander Scriabine. Chemical Heritage Foundation, 1999. p 185 ISBN 9780941901215

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.